US 12,065,464 B2
2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
Eric Anderson, Southlake, TX (US); Xiaofeng Liu, Coppell, TX (US); and Andrea Decker, Basel (CH)
Assigned to REATA PHARMACEUTICALS HOLDINGS, LLC, Plano, TX (US)
Filed by REATA PHARMACEUTICALS HOLDINGS, LLC, Plano, TX (US)
Filed on Jun. 25, 2021, as Appl. No. 17/304,778.
Application 17/304,778 is a continuation of application No. 15/622,568, filed on Jun. 14, 2017, granted, now 11,078,230.
Application 15/622,568 is a continuation of application No. 14/625,829, filed on Feb. 19, 2015, granted, now 9,701,709, issued on Jul. 11, 2017.
Application 14/625,829 is a continuation of application No. 13/869,833, filed on Apr. 24, 2013, granted, now 8,993,640, issued on Mar. 31, 2015.
Claims priority of provisional application 61/780,444, filed on Mar. 13, 2013.
Claims priority of provisional application 61/775,288, filed on Mar. 8, 2013.
Claims priority of provisional application 61/687,669, filed on Apr. 27, 2012.
Prior Publication US 2021/0355156 A1, Nov. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07J 63/00 (2006.01); A61K 31/277 (2006.01); C07C 255/47 (2006.01)
CPC C07J 63/008 (2013.01) [A61K 31/277 (2013.01); C07C 255/47 (2013.01)] 18 Claims
 
1. An in vitro method of activating the antioxidant/anti-inflammatory Keap1/Nrf2/ARE pathway in a cell, the method comprising contacting the cell with an effective amount of

OG Complex Work Unit Chemistry
a compound of the formula or a pharmaceutically acceptable salt thereof.